A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer.

Udai Banerji, Robert H. Jones, Daniel Castellano et al.|Journal of Clinical Oncology|2019

Cited by 20